Evidence map›Paper›PMID 40095335›Full record

ArticleInternational journal of clinical oncology2025

Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer.

Yoshinori Kikuchi, Yoko Oshima, Muneharu Fujisaki, Mao Tsuru, Hidejiro Urakami, Sakae Nagaoka, Nobue Futawatari, Satoshi Yajima, Hideaki Shimada

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoshinori KikuchiDepartment of Clinical Oncology, Faculty of Medicine, Toho University, Tokyo, Japan.
Yoko OshimaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Tokyo, Japan. oshima@med.toho-u.ac.jp.ORCID http://orcid.org/0000-0003-1260-4437
Muneharu FujisakiDepartment of Surgery, Jikei University School of Medicine, Tokyo, Japan.
Mao TsuruNTT Medical Center Tokyo, Tokyo, Japan.
Hidejiro UrakamiNational Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Sakae NagaokaDepartment of Gastroesophageal Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Nobue FutawatariDepartment of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan.
Satoshi YajimaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Tokyo, Japan.
Hideaki ShimadaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRamucirumab with either solvent-based or nanoparticle albumin-bound paclitaxel is a standard second-line treatment for advanced gastric cancer. Reportedly, nanoparticle albumin-bound paclitaxel has activated the immune system, but the efficacy of taxane-based agents before nivolumab remains unclear. Therefore, we investigated the prognostic effect of ramucirumab with solvent-based or nanoparticle albumin-bound paclitaxel as second-line therapy, followed by nivolumab as third-line therapy.

methodsThis retrospective study enrolled 115 patients with gastric cancer treated with ramucirumab in combination with solvent-based paclitaxel or nanoparticle albumin-bound paclitaxel from 2017 to 2019 at six hospitals. All patients received nivolumab as a third-line therapy. Ramucirumab + solvent-based paclitaxel and ramucirumab + nanoparticle albumin-bound paclitaxel were administered to 57 and 58 patients, respectively.

resultsThe progression-free survival of the ramucirumab + solvent-based paclitaxel group was slightly better than that of the ramucirumab + nanoparticle albumin-bound paclitaxel group but with no statistically significant difference (5.3 months vs. 4.2 months). Contrary, the overall survival of the ramucirumab + nanoparticle albumin-bound paclitaxel group was slightly better than the ramucirumab + solvent-based paclitaxel group but with no statistically significant difference (19.0 months vs. 12.5 months). The multivariate analysis of progression-free survival revealed that ramucirumab + nanoparticle albumin-bound paclitaxel was an independent risk factor for poor prognosis, whereas ramucirumab + nanoparticle albumin-bound paclitaxel was an independent factor for good overall survival.

conclusionsRamucirumab + nanoparticle albumin-bound paclitaxel may prolong overall survival when administered before nivolumab, despite its limited effect on progression-free survival.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNivolumabStomach NeoplasmsTaxoidsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPaclitaxelPrognosisProgression-Free SurvivalRamucirumabAntibodies, Monoclonal, HumanizedNivolumabPaclitaxelRamucirumabTaxoidsGastric cancerNanoparticle albumin-bound paclitaxelNivolumabPrognostic factorRamucirumabSolvent-based paclitaxel

Identifiers

PMID40095335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.